BV (Adcetris®, Seattle Genetics, Inc.)is an ADC composed of a chimeric anti-CD30 IgG1 antibody covalently linked to the microtubule-disrupting small-molecule MMAE via a cleavable valine-citrulline linker.51 In 2011, BV was approved by the FDA to treat patients with systemic anaplastic large-cell lymphoma (ALCL) and relapsed or refractory CD30-positive Hodgkin lymphoma (HL). The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.